Abstract
In April 2005, exenatide (Byetta; Amylin/Eli Lilly) was approved by the US FDA as an adjunctive therapy to improve blood-sugar control in patients with type 2 diabetes. It is the first in a new class of drugs that mimic the activity of natural glucoregulatory peptides known as incretins.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Clarithromycin prevents preterm birth and neonatal mortality by dampening alarmin-induced maternal–fetal inflammation in mice
BMC Pregnancy and Childbirth Open Access 20 June 2022
-
Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy
Nature Communications Open Access 24 November 2017
-
Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation
DARU Journal of Pharmaceutical Sciences Open Access 04 September 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Moller, D. E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414, 821–827 (2001).
Goke, R. et al. Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting β-cells. J. Biol. Chem. 268, 19650–19655 (1993).
Joy, S. V. et al. Incretin mimetics as emerging treatments for type 2 diabetes. Ann. Pharmacother. 39, 110–118 (2005).
FDA labelling information [online], <http://www.fda.gov/cder/foi/label/2005/021773lbl.pdf> (2005).
Buse, J. B. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27, 2628–2635 (2004).
Kendall, D. M. et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28, 1083–1091 (2005).
DeFronzo, R. A. et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28, 1092–1100 (2005).
U.K. Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44, 1249–1258 (1995).
Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813–820 (2001).
Brownlee, M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54, 1615–1625 (2005).
International Diabetes Federation <http://www.idf.org/>.
American Diabetes Association <http://www.diabetes.org/>.
IMS Health analysis, IMS MIDAS Quantum, MAT (Dec 2004).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Davidson, M., Bate, G. & Kirkpatrick, P. Exenatide. Nat Rev Drug Discov 4, 713–714 (2005). https://doi.org/10.1038/nrd1828
Issue Date:
DOI: https://doi.org/10.1038/nrd1828
This article is cited by
-
Clarithromycin prevents preterm birth and neonatal mortality by dampening alarmin-induced maternal–fetal inflammation in mice
BMC Pregnancy and Childbirth (2022)
-
GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis
Acta Pharmacologica Sinica (2022)
-
Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation
DARU Journal of Pharmaceutical Sciences (2017)
-
Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy
Nature Communications (2017)
-
GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans—PK/PD and Safety
Clinical Pharmacology & Therapeutics (2014)